$6.76 Billion is the total value of SUVRETTA CAPITAL MANAGEMENT, LLC's 106 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KZR | KEZAR LIFE SCIENCES INC | $8,403,000 | +14.2% | 1,409,956 | 0.0% | 0.12% | +18.1% | |
| MIST | MILESTONE PHARMACEUTICALS IN | $4,929,000 | -13.6% | 851,291 | 0.0% | 0.07% | -9.9% | |
| JWSWS | JAWS ACQUISITION CORP*w exp 99/99/999 | $2,145,000 | +17.8% | 674,566 | 0.0% | 0.03% | +23.1% | |
| BLSA | BCLS ACQUISITION CORP | $2,114,000 | -5.1% | 200,000 | 0.0% | 0.03% | -3.1% | |
| TMPM | TURMERIC ACQUISITION CORPcl a | $1,954,000 | -2.3% | 200,000 | 0.0% | 0.03% | 0.0% | |
| WPFWS | FOLEY TRASIMENE ACQUISTN COR*w exp 05/26/202 | $1,239,000 | -36.8% | 774,375 | 0.0% | 0.02% | -35.7% | |
| EUCR | EUCRATES BIOMEDICAL ACQU COR | $998,000 | -0.7% | 99,999 | 0.0% | 0.02% | +7.1% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $560,000 | -12.6% | 50,000 | 0.0% | 0.01% | -11.1% | |
| EUCRW | EUCRATES BIOMEDICAL ACQU COR*w exp 10/23/202 | $42,000 | -80.6% | 33,333 | 0.0% | 0.00% | -66.7% | |
| TMPMW | TURMERIC ACQUISITION CORP*w exp 10/08/202 | $67,000 | -44.6% | 66,666 | 0.0% | 0.00% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ADOBE SYSTEMS INCORPORATED | 33 | Q4 2021 | 13.2% |
| CONSTELLATION BRANDS INC | 20 | Q4 2018 | 10.9% |
| AMAZON COM INC | 20 | Q3 2023 | 8.0% |
| UNITEDHEALTH GROUP INC | 20 | Q3 2023 | 5.7% |
| IQVIA HLDGS INC | 19 | Q3 2023 | 7.3% |
| RESTAURANT BRANDS INTL INC | 18 | Q3 2019 | 8.9% |
| UNION PAC CORP | 17 | Q2 2023 | 5.1% |
| META PLATFORMS INC | 16 | Q3 2023 | 10.9% |
| COPART INC | 15 | Q4 2021 | 2.3% |
| SUTRO BIOPHARMA INC | 15 | Q3 2023 | 1.9% |
View SUVRETTA CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Zura Bio Ltd | June 15, 2023 | 2,850,000 | 6.6% |
| InflaRx N.V. | April 24, 2023 | 5,733,910 | 10.3% |
| Benitec Biopharma Inc. | April 18, 2023 | 3,020,214 | 10.0% |
| Aeglea BioTherapeutics, Inc. | February 13, 2023 | 6,376,373 | 10.0% |
| Bolt Biotherapeutics, Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Cano Health, Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Disc Medicine, Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| OTONOMY, INC.Sold out | February 13, 2023 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 13, 2023 | 0 | 0.0% |
View SUVRETTA CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-05-02 |
| SC 13D | 2024-04-29 |
| SC 13G | 2024-04-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View SUVRETTA CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.